Overview of the Upcoming Extraordinary General Meeting
On October 3, 2025, argenx SE (NASDAQ: ARGX), a leader in immunology, issues an important announcement about its forthcoming Extraordinary General Meeting. This significant gathering is set for November 18, 2025. During the meeting, shareholders will engage in vital discussions regarding the company's future plans and strategic decisions.
Meeting Details
The meeting will take place at 14:00 CET at the offices of Freshfields LLP, located in Amsterdam. All shareholders and individuals with voting rights are warmly encouraged to participate. This event will provide a platform for open dialogue about the company's direction, fostering transparency and shareholder engagement.
Access to Meeting Information
Shareholders can find formal notifications, including details on attending in person or by proxy, on the argenx official website. This includes registration requirements and the e-voting system information, creating a more streamlined approach for all participants.
Agenda Highlights
A key item on the agenda is the proposal for a revised remuneration policy. This aspect will be crucial in ensuring that argenx attracts top talent while aligning with shareholder expectations. All related documents and the full agenda will be accessible through the company's website, providing transparency and insight for stakeholders.
Encouraging Voting Participation
The company emphasizes the importance of utilizing voting by electronic proxy. This option not only simplifies the process but also encourages active participation from shareholders who may not attend in person.
About argenx
As a global immunology company, argenx is dedicated to improving the lives of individuals affected by severe autoimmune diseases. Through innovative partnerships and its Immunology Innovation Program, argenx aims to transform breakthrough discoveries into effective antibody-based treatments. The company is actively commercializing the first approved neonatal Fc receptor blocker while further investigating possibilities across various therapeutic areas.
Company’s Growth and Achievements
Recently, argenx has made significant strides in the biopharmaceutical arena, reinforcing its position as a pioneer in immunology. By developing advanced therapies that address critical health needs, argenx is setting a standard for excellence in patient care and treatment outcomes. With ongoing research and development efforts, the company is poised to expand its influence and deliver innovative solutions to the medical community.
Contact Information
For additional details, stakeholders can reach out to the media representative, Ben Petok, via email at BPetok@argenx.com. For investor inquiries, Alexandra Roy is available at aroy@argenx.com. Open lines of communication foster constructive dialogue between the company and its stakeholders, ensuring everyone can stay informed.
Frequently Asked Questions
What is the purpose of the Extraordinary General Meeting?
The meeting aims to discuss critical company updates and proposed policies, including a revised remuneration approach.
When and where will the meeting be held?
The meeting is scheduled for November 18, 2025, at 14:00 CET at Freshfields LLP in Amsterdam.
How can shareholders participate?
Shareholders can attend in person or vote electronically by proxy for their convenience.
What is argenx's primary focus as a company?
argenx focuses on developing therapies for severe autoimmune diseases and strives to improve patient outcomes through innovative treatments.
Who can stakeholders contact for more information?
Media inquiries can be directed to Ben Petok, while investors can reach out to Alexandra Roy for specific investment-related questions.
